Q3 2023 Results - Reimagining Medicine
Company overview
Financial review
Conclusions
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
opnurasib - KRAS inhibitor
NCT05132075 KontRASt-02 (CJDQ443B12301)
Indication
Non-small cell lung cancer, 2/3L
Phase
Phase 3
Patients
360
Primary
Progression free survival (PFS)
Outcome
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
Measures
Arms
Intervention
Target
Patients
Arm 1 Experimental: JDQ443
Arm 2 Active Comparator: Participant will be treated with docetaxel following
local guidelines as per standard of care and product labels
Patients with advanced non-small cell lung cancer (NSCLC) harboring a KRAS
G12C mutation who have been previously treated with a platinum-based
chemotherapy and immune checkpoint inhibitor therapy either in sequence or
in combination.
Readout
Milestone(s)
Publication
2024
NA
71 Investor Relations | Q3 2023 Results
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation